Filter

  • Advanced Filters:

  • to
  • Specific Data Sources:

    All Edit

    Select All  |  Select None

Reset filters

DeepDyve - Search, Rent, Read
The easiest way for you to get scholarly articles:

  • Millions of articles from over 6,000 authoritative journals.
  • Get any 40 rentable articles for just $40 a month.
  • Read rented articles for an entire year.
  • Unused rentals get rolled over.

Bookmark

Enhanced Growth of Pancreatic Tumors in SPARC-Null Mice Is Associated With Decreased Deposition of Extracellular Matrix and Reduced Tumor Cell Apoptosis11Supported in part by NIH grants (F32 HL10352 to R.A. Brekken and R01 GM40711 and R01 HL59574 to E.H. Sage), Gilbertson Foundation grant to the Hope Heart Institute, National Science Foundation grant (EEC-959161) to the University of Washington Engineered Biomaterials Center, American Cancer Society and Simmons Comprehensive Cancer Center Award (47411/56540 to R.A. Brekken), and Helsinki University Central Hospital Research Funds (EV0, Finland to P.A. Puolakkainen).Note P.A. Puolakkainen and R.A. Brekken contributed equally to this work.

Puolakkainen, Pauli A.; Brekken, Rolf A.; Muneer, Sabeeha; Sage, E. Helene
Molecular Cancer Research , Volume 2 (4): 215 American Association of Cancer ResearchApr 1, 2004

Preview Only

Enhanced Growth of Pancreatic Tumors in SPARC-Null Mice Is Associated With Decreased Deposition of Extracellular Matrix and Reduced Tumor Cell Apoptosis11Supported in part by NIH grants (F32 HL10352 to R.A. Brekken and R01 GM40711 and R01 HL59574 to E.H. Sage), Gilbertson Foundation grant to the Hope Heart Institute, National Science Foundation grant (EEC-959161) to the University of Washington Engineered Biomaterials Center, American Cancer Society and Simmons Comprehensive Cancer Center Award (47411/56540 to R.A. Brekken), and Helsinki University Central Hospital Research Funds (EV0, Finland to P.A. Puolakkainen).Note P.A. Puolakkainen and R.A. Brekken contributed equally to this work.

Abstract

SPARC, a matricellular glycoprotein, modulates cellular interaction with the extracellular matrix (ECM). Tumor growth and metastasis occur in the context of the ECM, the levels and deposition of which are controlled in part by SPARC. Tumor-derived SPARC is reported to stimulate or retard tumor progression depending on the tumor type, whereas the function of host-derived SPARC in tumorigenesis has not been explored fully. To evaluate the function of endogenous SPARC, we have examined the growth of pancreatic tumors in SPARC-null ( SP −/− ) mice and their wild-type ( SP +/+ ) counterparts. Mouse pancreatic adenocarcinoma cells injected s.c. grew significantly faster in SP −/− mice than cells injected into SP +/+ animals, with mean tumor weights at sacrifice of 0.415 ± 0.08 and 0.086 ± 0.03 g ( P < 0.01), respectively. Lack of endogenous SPARC resulted in decreased collagen deposition and fiber formation, alterations in the distribution of tumor-infiltrating macrophages, and decreased tumor cell apoptosis. There was no difference in microvessel density of tumors from SP −/− or SP +/+ mice. However, tumors grown in SP −/− had a lower percentage of blood vessels that expressed smooth muscle α-actin, a marker of pericytes. These data reflect the importance of ECM deposition in regulating tumor growth and demonstrate that host-derived SPARC is a critical factor in the response of host tissue to tumorigenesis.
Loading next page...
1 Page

Preview Only. This article cannot be rented because we do not currently have permission from the publisher.

 
/lp/american-association-of-cancer-research/enhanced-growth-of-pancreatic-tumors-in-sparc-null-mice-is-associated-wnYGLTuhZO
Title
Enhanced Growth of Pancreatic Tumors in SPARC-Null Mice Is Associated With Decreased Deposition of Extracellular Matrix and Reduced Tumor Cell Apoptosis11Supported in part by NIH grants (F32 HL10352 to R.A. Brekken and R01 GM40711 and R01 HL59574 to E.H. Sage), Gilbertson Foundation grant to the Hope Heart Institute, National Science Foundation grant (EEC-959161) to the University of Washington Engineered Biomaterials Center, American Cancer Society and Simmons Comprehensive Cancer Center Award (47411/56540 to R.A. Brekken), and Helsinki University Central Hospital Research Funds (EV0, Finland to P.A. Puolakkainen).Note P.A. Puolakkainen and R.A. Brekken contributed equally to this work.
Author(s)
Puolakkainen, Pauli A.; Brekken, Rolf A.; Muneer, Sabeeha; Sage, E. Helene
Journal
Molecular Cancer Research , Volume 2 (4): 215 American Association of Cancer Research – Apr 1, 2004
Publisher
AACR
Copyright
Copyright © 2010 American Association for Cancer Research
ISSN
1541-7786
eISSN
1557-3125
Publisher site
Get PDF